{
    "clinical_study": {
        "@rank": "137948", 
        "acronym": "HOPEMD", 
        "arm_group": [
            {
                "arm_group_label": "Cabaletta 15gr.", 
                "arm_group_type": "Experimental", 
                "description": "weekly IV of Cabaletta 15gr."
            }, 
            {
                "arm_group_label": "Cabaletta 30gr.", 
                "arm_group_type": "Experimental", 
                "description": "weekly IV of Cabaletta 30gr."
            }
        ], 
        "brief_summary": {
            "textblock": "The Purpose of this study is to assess the Safety, Tolerability and Efficacy of Intravenous\n      Cabaletta\u00ae in Oculopharyngeal Muscular Dystrophy  (OPMD) Patients."
        }, 
        "brief_title": "Safety Tolerability and Efficacy Study of Cabaletta to Treat Oculopharyngeal Muscular Dystrophy (OPMD) Patients", 
        "condition": "Oculopharyngeal Muscular Dystrophy", 
        "condition_browse": {
            "mesh_term": [
                "Muscular Dystrophies", 
                "Muscular Dystrophy, Oculopharyngeal"
            ]
        }, 
        "eligibility": {
            "criteria": {
                "textblock": "Inclusion Criteria:\n\n          -  Males and females\n\n          -  18 - 80 years (inclusive) of age\n\n          -  Clinically and genetically diagnosed as OPMD\n\n          -  Moderate dysphagia (abnormal drinking test at screening and on the first dosing day,\n             before drug administration)\n\n          -  Patients who provide written informed consent to participate in the study\n\n          -  Body Mass Index (BMI) <30 kg/m2\n\n        Exclusion Criteria:\n\n          -  Diabetes mellitus type 1 or 2\n\n          -  Other major diseases, e.g.:  renal failure (creatinine clearance <60ml/min), liver\n             failure and chronic  liver diseases (e.g. hepatitis B or C) , HIV carriers,\n             tuberculosis, SLE, rheumatoid polyarthritis, sarcoidosis, collagenosis\n\n          -  Uncontrolled heart disease , CHF,\n\n          -  Other neuromuscular diseases\n\n          -  Other disorders associated with esophageal dysphagia: e.g. severe gastroesophageal\n             reflux (GERD), esophageal stricture due to mechanical or chemical trauma, infection\n             (e.g. esophageal moniliasis), drug-induced dysphagia (e.g. bisphosphonates),\n             esophageal rings and webs, spastic motility disorders of the esophagus.\n\n          -  History of malignancy (except non-invasive skin malignancy)\n\n          -  History of neck irradiation\n\n          -  Pregnant or currently lactating women\n\n          -  Obesity (BMI\u2265 30) and associated morbidity\n\n          -  Prior pharyngeal myotomy\n\n          -  Weight loss of more than 10% in the last 12 months.\n\n          -  Known hypersensitivity to  any ingredients in the injection\n\n          -  Patient receiving anticoagulant treatment (e.g. warfarin)"
            }, 
            "gender": "Both", 
            "healthy_volunteers": "No", 
            "maximum_age": "80 Years", 
            "minimum_age": "18 Years"
        }, 
        "enrollment": {
            "#text": "28", 
            "@type": "Anticipated"
        }, 
        "firstreceived_date": "December 8, 2013", 
        "has_expanded_access": "No", 
        "id_info": {
            "nct_id": "NCT02015481", 
            "org_study_id": "BBCO-001"
        }, 
        "intervention": {
            "arm_group_label": [
                "Cabaletta 15gr.", 
                "Cabaletta 30gr."
            ], 
            "intervention_name": "Cabaletta", 
            "intervention_type": "Drug"
        }, 
        "is_fda_regulated": "No", 
        "keyword": "Case control, safety, tolerability, efficacy.", 
        "lastchanged_date": "May 22, 2014", 
        "location": [
            {
                "contact": {
                    "email": "bernard.brais@mcgill.ca", 
                    "last_name": "Bernard Brais, MD", 
                    "phone": "+1-514-3982667"
                }, 
                "facility": {
                    "address": {
                        "city": "Montreal", 
                        "country": "Canada", 
                        "state": "Quebec", 
                        "zip": "H3A 2B4"
                    }, 
                    "name": "Montreal Neurological Institute, McGill University"
                }, 
                "investigator": {
                    "last_name": "Bernard Brais, MD", 
                    "role": "Principal Investigator"
                }, 
                "status": "Not yet recruiting"
            }, 
            {
                "contact": {
                    "email": "CARACO@hadassah.org.il", 
                    "last_name": "Yoseph Caraco, MD", 
                    "phone": "972 2 6779374"
                }, 
                "facility": {
                    "address": {
                        "city": "Jerusalem", 
                        "country": "Israel", 
                        "zip": "91120"
                    }, 
                    "name": "Hadassah medical center"
                }, 
                "investigator": {
                    "last_name": "Yoseph Caraco, MD", 
                    "role": "Principal Investigator"
                }, 
                "status": "Recruiting"
            }
        ], 
        "location_countries": {
            "country": [
                "Canada", 
                "Israel"
            ]
        }, 
        "number_of_arms": "2", 
        "official_title": "A Multi-Center, Randomized, Double-Blind, Dose-Escalation and Parallel-Group Dose-Controlled Study, to Assess Safety, Tolerability and Efficacy of Intravenous Cabaletta\u00ae in OPMD Patients", 
        "overall_contact": {
            "email": "CARACO@hadassah.org.il", 
            "last_name": "Yoseph Caraco, M.D", 
            "phone": "+972 2 6779374"
        }, 
        "overall_official": [
            {
                "affiliation": "Hadassah Medical Center", 
                "last_name": "Yoseph Caraco, M.D", 
                "role": "Principal Investigator"
            }, 
            {
                "affiliation": "Montreal Neurological Institute, McGill University", 
                "last_name": "Bernard Brais, MD", 
                "role": "Principal Investigator"
            }
        ], 
        "overall_status": "Recruiting", 
        "oversight_info": {
            "authority": [
                "Israel: Ministry of Health", 
                "Canada: Health Canada"
            ], 
            "has_dmc": "No"
        }, 
        "phase": "Phase 2", 
        "primary_completion_date": {
            "#text": "October 2014", 
            "@type": "Anticipated"
        }, 
        "primary_outcome": [
            {
                "measure": "vital signs", 
                "safety_issue": "Yes", 
                "time_frame": "28 weeks"
            }, 
            {
                "measure": "safety lab tests", 
                "safety_issue": "Yes", 
                "time_frame": "28 weeks"
            }, 
            {
                "measure": "Adverse Events", 
                "safety_issue": "Yes", 
                "time_frame": "28 weeks"
            }
        ], 
        "required_header": {
            "download_date": "ClinicalTrials.gov processed this data on June 04, 2014", 
            "link_text": "Link to the current ClinicalTrials.gov record.", 
            "url": "http://clinicaltrials.gov/show/NCT02015481"
        }, 
        "responsible_party": {
            "responsible_party_type": "Sponsor"
        }, 
        "secondary_outcome": {
            "measure": "Changes in disease markers", 
            "safety_issue": "No", 
            "time_frame": "28 weeks"
        }, 
        "source": "Bioblast Pharma Ltd.", 
        "sponsors": {
            "lead_sponsor": {
                "agency": "Bioblast Pharma Ltd.", 
                "agency_class": "Industry"
            }
        }, 
        "start_date": "February 2014", 
        "study_design": "Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator, Outcomes Assessor), Primary Purpose: Treatment", 
        "study_type": "Interventional", 
        "verification_date": "December 2013"
    }
}